Institutional shares held 3.55 Million
11.7K calls
0 puts
Total value of holdings $25.4M
$83K calls
$0 puts
Market Cap $306M
42,746,800 Shares Out.
Institutional ownership 8.3%
# of Institutions 6


Latest Institutional Activity in GTHX

Top Purchases

Q2 2024
Black Rock Inc. Shares Held: 3.08M ($22M)
Q2 2024
Woodline Partners LP Shares Held: 1.36M ($9.74M)
Q2 2024
State Street Corp Shares Held: 828K ($5.92M)
Q2 2024
Geode Capital Management, LLC Shares Held: 1.08M ($7.72M)
Q2 2024
Acadian Asset Management LLC Shares Held: 928K ($6.64M)

Top Sells

Q2 2024
Bank Of America Corp Shares Held: 78.4K ($560K)
Q2 2024
Jane Street Group, LLC Shares Held: 64.9K ($464K)
Q2 2024
Goldman Sachs Group Inc Shares Held: 211K ($1.51M)
Q2 2024
Man Group PLC Shares Held: 128K ($913K)
Q2 2024
Citigroup Inc Shares Held: 10.7K ($76.8K)

About GTHX

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.


Insider Transactions at GTHX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.12M Shares
From 14 Insiders
Grant, award, or other acquisition 1.09M shares
Exercise of conversion of derivative security 28.6K shares
Sell / Disposition
2.32M Shares
From 32 Insiders
Sale (or disposition) back to the issuer 1.52M shares
Disposition due to a tender of shares in a change of control transaction 607K shares
Open market or private sale 195K shares

Track Institutional and Insider Activities on GTHX

Follow G1 Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GTHX shares.

Notify only if

Insider Trading

Get notified when an G1 Therapeutics, Inc. insider buys or sells GTHX shares.

Notify only if

News

Receive news related to G1 Therapeutics, Inc.

Track Activities on GTHX